×
About 1,985 results

ALLMedicine™ Mucormycosis Center

Research & Reviews  705 results

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
https://clinicaltrials.gov/ct2/show/NCT03816176

Jul 1st, 2022 - Treatment will begin on Day 1 and then participants will be followed for 60 days post-last dose for safety. Treatment will be administered until the participant has a successful outcome or for a maximum duration of 84 days (IA) or 180 days (IM), w...

Histomorphological features of mucormycosis with rise and fall of COVID-19 pandemic.
https://doi.org/10.1016/j.prp.2022.153981
Pathology, Research and Practice; Ganesan N, Sivanandam S

Jun 25th, 2022 - Due to Corona Virus disease -19, India saw a surge of mucormycosis cases, associated with high death rate. India, during the month of May to July 2021 saw a surge of mucormycosis from all states, with close to 50,000 cases just in a span of 3 mont...

Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the...
https://doi.org/10.1097/INF.0000000000003608
The Pediatric Infectious Disease Journal; Loeffen YGT, Scharloo F et. al.

Jun 16th, 2022 - Mucormycosis is classified as the third leading cause of invasive fungal disease in immunocompromised patients and is characterized by high morbidity and mortality (33%-56%). The aim of this study is to describe presentation, treatment and outcome...

Decreased mortality in COVID Associated Mucormycosis with Aspirin use: A Retrospective ...
https://doi.org/10.1017/S0022215122001402
The Journal of Laryngology and Otology; Shaikh Z, Sarkar S et. al.

Jun 15th, 2022 - Decreased mortality in COVID Associated Mucormycosis with Aspirin use: A Retrospective Cohort Study.|2022|Shaikh Z,Sarkar S,Biswas R,Adhikari A,Hallur VK,|

A case series of mucormycosis after covid infection in two hospitals.
https://doi.org/10.1016/j.jormas.2022.06.003
Journal of Stomatology, Oral and Maxillofacial Surgery; Martins HDD, Pares AR et. al.

Jun 15th, 2022 - This paper aims to discuss clinical aspects of mucormycosis. This case series was conducted in two services, comprising six mucormycosis cases during COVID-19 pandemic. About gender, there are 4 (66.7%) males and 2 (33.3%) females with mean age (4...

see more →

Guidelines  3 results

Global guideline for the diagnosis and management of mucormycosis: an initiative of the...
https://doi.org/10.1016/S1473-3099(19)30312-3
The Lancet. Infectious Diseases; Cornely OA, Alastruey-Izquierdo A et. al.

Nov 9th, 2019 - Mucormycosis is a difficult to diagnose rare disease with high morbidity and mortality. Diagnosis is often delayed, and disease tends to progress rapidly. Urgent surgical and medical intervention is lifesaving. Guidance on the complex multidiscipl...

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormyc...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5394968
Haematologica Tissot F, Agrawal S et. al.

Dec 25th, 2016 - The European Conference on Infections in Leukemia (ECIL) provides recommendations for diagnostic strategies and prophylactic, pre-emptive or targeted therapy strategies for various types of infection in patients with hematologic malignancies or he...

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormyco...
https://doi.org/10.1111/1469-0691.12371
Clinical Microbiology and Infection : the Official Public... Cornely OA, Arikan-Akdagli S et. al.

Feb 1st, 2014 - These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis. Only a few of the numerous recommendations can...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  20 results

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants
https://clinicaltrials.gov/ct2/show/NCT03816176

Jul 1st, 2022 - Treatment will begin on Day 1 and then participants will be followed for 60 days post-last dose for safety. Treatment will be administered until the participant has a successful outcome or for a maximum duration of 84 days (IA) or 180 days (IM), w...

Biomarkers for Invasive Mucormycosis
https://clinicaltrials.gov/ct2/show/NCT05406037

Jun 6th, 2022 - Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization. Prompt initiation of adequate...

Pharmacokinetics of Isavuconazole in Patients in the Intensive Care Unit
https://clinicaltrials.gov/ct2/show/NCT04777058

May 20th, 2022 - Fungal infections are a serious threat to immunocompromised patients and represent a major burden in the critical care setting. The azole antifungal drugs are the most important drugs for managing infections caused by Aspergillus moulds and the pr...

Mucormycosis in COVID-19
https://clinicaltrials.gov/ct2/show/NCT04935463

May 3rd, 2022 - The purpose is to allow phsyician reporters to contribute to MUNCO registry. Mucormycosis in COVID-19 is a rapidly escalating medical emergency reported in high numbers in India during the ongoing coronavirus surge. There is very little known abou...

COVID-19 and Rhino-orbital Mucormycosis
https://clinicaltrials.gov/ct2/show/NCT05212961

Apr 6th, 2022 - Detect the clinical presentation and outcome of post covid-19 fungal mucormycosis in patients referred to Minia university Hospital.

see more →

News  64 results

COVID-Associated Ocular Mucormycosis Outbreak Case Study Reveals High-Risk Group for Deadly Complication
https://www.medscape.com/viewarticle/965652

Dec 28th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Earlier this year, hospitals in India were not only dealing with the coronavirus pandemic but also a surge in a potentially lethal fungal infectio...

CAR T-Cell Therapy UCARTCS1A Shows Early Activity in Relapsed/Refractory Myeloma
https://www.onclive.com/view/car-t-cell-therapy-ucartcs1a-shows-early-activity-in-relapsed-refractory-myeloma

Aug 17th, 2021 - UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 tri...

Watch for mucormycosis in COVID-19 patients
https://www.mdedge.com/infectiousdisease/article/242052/invasive-fungal-infections/watch-mucormycosis-covid-19-patients

Jun 24th, 2021 - Key clinical point: Mucormycosis cases surged after the appearance of COVID-19, but adjunct surgery in COVID-19 patients with mucormycosis improved clinical outcomes. Major finding: The mortality rate among 99 COVID-19 patients with mucormycosis w.

Yanked COVID Gene Sequences; Britney Wants to Be Freed; Smuggling Remdesivir
https://www.medpagetoday.com/infectiousdisease/covid19/93262

Jun 24th, 2021 - Note that some links may require registration or subscription. COVAX will be focusing less on partnering with rich countries as part of an internal overhaul. (Reuters) Why were early Chinese COVID cases purged from a gene sequencing database? (Wal...

Skip Routine Probiotics for Preemies, AAP Says
https://www.medscape.com/viewarticle/951764

May 25th, 2021 - The American Academy of Pediatrics (AAP) now recommends against the routine administration of probiotics to preterm infants, particularly the most vulnerable (those whose birth weight is <1000 g), for the treatment or prevention of necrotizing ent...

see more →